

Paolo Gionchetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2145381/publications.pdf>

Version: 2024-02-01

206
papers

21,232
citations

15495

65
h-index

9854

141
g-index

210
all docs

210
docs citations

210
times ranked

13783
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 76-84.	0.9	6
2	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 2-17.	0.6	288
3	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. <i>Digestive and Liver Disease</i> , 2022, 54, 440-451.	0.4	22
4	New endoscopic capsule vs upper gastrointestinal endoscopy in preoperative work-up of obese candidate for bariatric surgery: Relevance of a pilot study in the COVID-19 era. <i>Endoscopy International Open</i> , 2022, 10, E183-E191.	0.9	0
5	PANENTERIC CAPSULE ENDOSCOPY TO CHARACTERIZE CROHN'S DISEASE PHENOTYPES AND PREDICT CLINICAL OUTCOMES IN CHILDREN AND ADULTS. <i>Gastrointestinal Endoscopy</i> , 2022, 95, AB429.	0.5	0
6	Long term remission after ileorectal anastomosis in Crohn's colitis. <i>Digestive and Liver Disease</i> , 2021, 53, 592-597.	0.4	4
7	COVID-19 in IBD: The experience of a single tertiary IBD center. <i>Digestive and Liver Disease</i> , 2021, 53, 271-276.	0.4	32
8	Baseline Histological Findings Do Not Predict the Risk of Subsequent Extension in Patients with Limited Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	0
9	Pouchitis: Clinical Features, Diagnosis, and Treatment. <i>International Journal of General Medicine</i> , 2021, Volume 14, 3871-3879.	0.8	11
10	Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. <i>Digestive and Liver Disease</i> , 2021, , .	0.4	2
11	An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1108-1117.	1.9	13
12	Refractory Complex Crohn's Perianal Fistulas: A Role for Autologous Microfragmented Adipose Tissue Injection. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 321-330.	0.9	38
13	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 4-22.	0.6	741
14	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 155-168.	0.6	478
15	Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality. <i>Digestive and Liver Disease</i> , 2020, 52, 506-515.	0.4	14
16	Performance of Capsule Endoscopy and Cross-Sectional Techniques in Detecting Small Bowel Lesions in Patients with Crohn's Disease. <i>Crohn's & Colitis</i> 360, 2020, 2, .	0.5	7
17	Ustekinumab for treating ulcerative colitis: an expert opinion. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1321-1329.	1.4	11
18	Usefulness of panoramic 344°-viewing in Crohn's disease capsule endoscopy: a proof of concept pilot study with the novel PillCam, Crohn's system. <i>BMC Gastroenterology</i> , 2020, 20, 97.	0.8	22

#	ARTICLE	IF	CITATIONS
19	Strictureplasty for Crohn's disease of the small bowel in the biologic era: long-term outcomes and risk factors for recurrence. <i>Techniques in Coloproctology</i> , 2020, 24, 711-720.	0.8	7
20	Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement. <i>Angiology</i> , 2020, 71, 689-697.	0.8	19
21	Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-9.	0.7	12
22	Budesonide MMX: efficacy and safety profile in the treatment of ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 607-613.	1.4	9
23	Implications of the Westernized Diet in the Onset and Progression of IBD. <i>Nutrients</i> , 2019, 11, 1033.	1.7	142
24	Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. <i>Digestive and Liver Disease</i> , 2019, 51, 613-620.	0.4	14
25	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019, 51, 632-639.	0.4	36
26	Predictors of early recurrence after strictureplasty for Crohn's disease of the small bowel during the years of biologics. <i>Digestive and Liver Disease</i> , 2019, 51, 663-668.	0.4	9
27	A current overview of corticosteroid use in active ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 557-561.	1.4	37
28	Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis. <i>Clinical and Experimental Immunology</i> , 2019, 196, 123-138.	1.1	27
29	Medical Treatment of Ulcerative Colitis: Does Traditional Therapy Still Have a Role?. <i>Updates in Surgery Series</i> , 2019, , 93-104.	0.0	0
30	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. <i>Advances in Therapy</i> , 2018, 35, 545-562.	1.3	16
31	Transabdominal salvage surgery after pouch failure in a tertiary center: A case-matched study. <i>Digestive and Liver Disease</i> , 2018, 50, 446-451.	0.4	9
32	Prepouch Ileitis After Ileal Pouch-anal Anastomosis: Patterns of Presentation and Risk Factors for Failure of Treatment. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 273-279.	0.6	24
33	Ustekinumab in the management of Crohn's disease: Expert opinion. <i>Digestive and Liver Disease</i> , 2018, 50, 653-660.	0.4	22
34	Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach. <i>Digestive Diseases</i> , 2018, 36, 346-353.	0.8	1
35	Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 360-369.e2.	0.5	29
36	The safety of beclomethasone dipropionate in the treatment of ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 963-969.	1.0	8

#	ARTICLE	IF	CITATIONS
37	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017, 49, 338-358.	0.4	42
38	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2017, 49, 604-617.	0.4	47
39	Probiotics, Prebiotics, and Antibiotics in IBD. , 2017, , 455-469.		1
40	Case-control Study on Dactylitis, Enthesitis, and Anterior Uveitis in Spondyloarthritis Associated with Inflammatory Bowel Diseases: Role of Coexistent Psoriasis. <i>Journal of Rheumatology</i> , 2017, 44, 1341-1346.	1.0	15
41	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 649-670.	0.6	1,324
42	Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts. <i>Digestive and Liver Disease</i> , 2017, 49, 1298-1305.	0.4	13
43	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 3-25.	0.6	1,547
44	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 135-149.	0.6	558
45	Real-time elastography for the detection of fibrotic and inflammatory tissue in patients with stricturing Crohn's disease. <i>Journal of Ultrasound</i> , 2017, 20, 273-284.	0.7	26
46	Risks and Benefits of Mucosal Healing With Combined Immunosuppression in Paediatric Crohn's Disease: A Complex Topic That Needs Careful Evaluation. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jiw220.	0.6	0
47	Can supplementation of phytoestrogens/insoluble fibers help the management of duodenal polyps in familial adenomatous polyposis?. <i>Carcinogenesis</i> , 2016, 37, 600-606.	1.3	8
48	European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly: Table 1.. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jiw188.	0.6	79
49	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2016, 48, 360-370.	0.4	34
50	IBD and spondyloarthritis: joint management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 9-10.	8.2	13
51	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , 2016, 150, 1568-1578.	0.6	251
52	European evidence based consensus on surgery for ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 4-25.	0.6	285
53	The therapeutic potential of antibiotics and probiotics in the treatment of pouchitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1175-1181.	1.4	19
54	The Probiotic VSL#3 Has Anti-inflammatory Effects and Could Reduce Endoscopic Recurrence After Surgery for Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 928-935.e2.	2.4	181

#	ARTICLE	IF	CITATIONS
55	Absence of change in the gray matter volume of patients with ulcerative colitis in remission: a voxel based morphometry study. <i>BioPsychoSocial Medicine</i> , 2015, 9, 1.	0.9	20
56	Inflammatory Bowel Diseases and Spondyloarthropathies. <i>Journal of rheumatology Supplement</i> , The, 2015, 93, 21-23.	2.2	31
57	Sporadic small bowel tumors detected by capsule endoscopy in patients with occult gastrointestinal bleeding. <i>Internal and Emergency Medicine</i> , 2015, 10, 781-785.	1.0	4
58	Attachment and quality of life in patients with inflammatory bowel disease. <i>International Journal of Colorectal Disease</i> , 2014, 29, 1291-1296.	1.0	31
59	The role of Budesonide-MMX in active ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 215-222.	1.4	9
60	Mucosal healing in pediatric Crohn's disease after anti-TNF therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 458-465.	0.8	36
61	Adenocarcinoma in Crohn's disease: the pathologist's experience in a tertiary referral centre of inflammatory bowel disease. <i>Pathology</i> , 2014, 46, 439-443.	0.3	4
62	Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1217-1221.	0.6	53
63	A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1485-1493.e2.	2.4	256
64	Oral beclomethasone dipropionate in chronic refractory pouchitis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 649-653.	0.6	37
65	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2014, 46, 963-968.	0.4	39
66	Sequential rescue therapy in steroid-refractory ulcerative colitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 521-523.	8.2	5
67	Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014, 13, 822-830.	2.5	84
68	Systems Biology Approaches for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2104-2114.	0.9	32
69	Functional magnetic resonance imaging study reveals differences in the habituation to psychological stress in patients with Crohn's disease versus healthy controls. <i>Journal of Behavioral Medicine</i> , 2013, 36, 477-487.	1.1	51
70	Four cases of carcinoid tumour in Crohn's disease: coincidence or correlation?. <i>International Journal of Colorectal Disease</i> , 2013, 28, 1743-1745.	1.0	5
71	Obscure gastrointestinal bleeding: single centre experience of capsule endoscopy. <i>Internal and Emergency Medicine</i> , 2013, 8, 681-687.	1.0	20
72	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 1-33.	0.6	422

#	ARTICLE	IF	CITATIONS
73	Drug delivery by polymeric micelles: an in vitro and in vivo study to deliver lipophilic substances to colonocytes and selectively target inflamed colon. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013, 9, 675-685.	1.7	21
74	New insights into the brain involvement in patients with Crohn's disease: a voxel-based morphometry study. <i>Neurogastroenterology and Motility</i> , 2013, 25, 147.	1.6	87
75	The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 501-512.	1.9	152
76	Adalimumab in active ulcerative colitis: A real-life observational study. <i>Digestive and Liver Disease</i> , 2013, 45, 738-743.	0.4	72
77	Risk of permanent stoma in extensive Crohn's colitis: the impact of biological drugs. <i>Colorectal Disease</i> , 2013, 15, 1115-1122.	0.7	37
78	Rescue therapy: ciclosporin or infliximab?. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 503-505.	1.3	1
79	News and controversy in inflammatory bowel disease treatment. <i>Italian Journal of Medicine</i> , 2013, , 179-186.	0.2	0
80	Clinical management of severe active ulcerative colitis in the TNF- α inhibitors era. <i>Italian Journal of Medicine</i> , 2013, 7, 272.	0.2	0
81	Eviendep [®] reduces number and size of duodenal polyps in familial adenomatous polyposis patients with ileal pouch-anal anastomosis. <i>World Journal of Gastroenterology</i> , 2013, 19, 5671.	1.4	18
82	Management and treatment of distal ulcerative colitis. <i>Italian Journal of Medicine</i> , 2013, 7, 265.	0.2	0
83	Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease. <i>Gastroenterology</i> , 2012, 142, 473-481.e4.	0.6	165
84	Probiotics, Prebiotics, and Antibiotics in Medical Management of Inflammatory Bowel Disease. , 2012, , 517-534.		1
85	The role of antibiotics and probiotics in pouchitis. <i>Annals of Gastroenterology</i> , 2012, 25, 100-105.	0.4	22
86	Author's reply. <i>Annals of Gastroenterology</i> , 2012, 25, 371.	0.4	0
87	Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 30-35.	2.4	316
88	Clinical course of microscopic colitis in a single-center cohort study. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 218-221.	0.6	19
89	The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease†. <i>Digestive and Liver Disease</i> , 2011, 43, 1-20.	0.4	125
90	Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 724-734.	1.9	146

#	ARTICLE	IF	CITATIONS
91	Distinct proteomic profiles characterise non-erosive from erosive reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 982-993.	1.9	5
92	Brain functional changes in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1769-1777.	0.9	65
93	Role of conventional therapies in the era of biological treatment in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2011, 17, 1797.	1.4	11
94	Cell proliferation of esophageal squamous epithelium in erosive and non-erosive reflux disease. <i>World Journal of Gastroenterology</i> , 2011, 17, 4496.	1.4	0
95	Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1180-1186.	0.9	86
96	Local Injection of Adalimumab for Perianal Crohn's Disease: Better Than Infliximab?. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1631.	0.9	29
97	Potential role of the cannabinoid receptor CB ₁ in the pathogenesis of erosive and non-erosive gastroesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 603-611.	1.9	9
98	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 63-101.	0.6	695
99	Adalimumab in a patient with steroid-dependent Crohn's disease. <i>Digestive and Liver Disease Supplements</i> , 2010, 4, 38-39.	0.2	0
100	Parental Bonding and Inflammatory Bowel Disease. <i>Psychosomatics</i> , 2010, 51, 14-21.	2.5	27
101	Parental Bonding and Inflammatory Bowel Disease. <i>Psychosomatics</i> , 2010, 51, 14-21.	2.5	22
102	Adult Attachment and Early Parental Experiences in Patients With Crohn's Disease. <i>Psychosomatics</i> , 2010, 51, 208-215.	2.5	34
103	Antibiotics and probiotics in chronic pouchitis: a comparative proteomic approach. <i>World Journal of Gastroenterology</i> , 2010, 16, 30-41.	1.4	12
104	Parvovirus B19 Infection Localized in the Intestinal Mucosa and Associated with Severe Inflammatory Bowel Disease. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1591-1595.	1.8	20
105	Implications of antioxidant enzymes in human gastric neoplasms. <i>International Journal of Molecular Medicine</i> , 2009, 24, 693-700.	1.8	27
106	Clinical guidelines for the management of pouchitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1424-1431.	0.9	111
107	Immunoregulatory activity of rifaximin associated with a resistant mutant of <i>Bifidobacterium infantis</i> . <i>International Journal of Antimicrobial Agents</i> , 2009, 33, 387-389.	1.1	7
108	Attualità e controversie nella terapia delle malattie infiammatorie croniche intestinali. <i>Italian Journal of Medicine</i> , 2009, 3, 179-186.	0.2	0

#	ARTICLE	IF	CITATIONS
109	Pouchitis. , 2009, , 195-205.		0
110	Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 759-764.	1.9	97
111	Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 250-255.	1.9	13
112	Interaction of probiotic <i>Lactobacillus</i> and <i>Bifidobacterium</i> strains with human intestinal epithelial cells: Adhesion properties, competition against enteropathogens and modulation of IL-8 production. <i>International Journal of Food Microbiology</i> , 2008, 125, 286-292.	2.1	344
113	European evidence-based Consensus on the management of ulcerative colitis: Special situations. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 63-92.	0.6	206
114	Corrigendum to "European evidence-based consensus on the management of ulcerative colitis: Special situations" [<i>J Crohns & Colitis</i> 2 (2008) 63-92]. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 191.	0.6	1
115	Cutaneous Manifestations in Inflammatory Bowel Diseases: Eight Cases of Psoriasis Induced by Anti-Tumor-Necrosis-Factor Antibody Therapy. <i>Dermatology</i> , 2007, 215, 295-300.	0.9	49
116	Ultrasound assessment of vascularization of the thickened terminal ileum wall in Crohn's disease patients using a low-mechanical index real-time scanning technique with a second generation ultrasound contrast agent. <i>European Journal of Radiology</i> , 2007, 62, 114-121.	1.2	125
117	Neuropeptide S Receptor 1 Gene Polymorphism Is Associated With Susceptibility to Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2007, 133, 808-817.	0.6	87
118	Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: A multicenter, randomized, double-blind study. <i>Digestive and Liver Disease</i> , 2007, 39, 329-337.	0.4	51
119	Potential role for the common cystic fibrosis ΔF508 mutation in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 531-536.	0.9	23
120	Oral budesonide in the treatment of chronic refractory pouchitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1231-1236.	1.9	129
121	Controlled study using wireless capsule endoscopy for the evaluation of the small intestine in chronic refractory pouchitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1311-1316.	1.9	35
122	Pre-pouch ileitis: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 964-964.	1.9	0
123	Sympathetic hyperactivity in patients with ulcerative colitis. <i>Clinical Autonomic Research</i> , 2007, 17, 217-220.	1.4	22
124	High-Dose Probiotics for the Treatment of Active Pouchitis. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 2075-2084.	0.7	179
125	Infliximab in the treatment of Crohn's disease. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 301-308.	0.9	32
126	Increased risk of breast cancer in first-degree relatives of Crohn's disease patientsAn IG-IBD study. <i>Digestive and Liver Disease</i> , 2006, 38, 18-23.	0.4	19

#	ARTICLE	IF	CITATIONS
127	Effects of probiotic bacteria on gastrointestinal motility in guinea-pig isolated tissue. <i>World Journal of Gastroenterology</i> , 2006, 12, 5987.	1.4	47
128	Antibiotics and probiotics in treatment of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2006, 12, 3306.	1.4	122
129	CT-guided percutaneous pelvic abscess drainage in Crohn's disease. <i>Techniques in Coloproctology</i> , 2006, 10, 99-105.	0.8	55
130	Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. <i>Gut</i> , 2006, 55, 833-841.	6.1	211
131	Antimicrobials in the Management of Inflammatory Bowel Disease. <i>Digestion</i> , 2006, 73, 77-85.	1.2	68
132	<i>Lactobacilli</i> , <i>bifidobacteria</i> and <i>E. coli</i> nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. <i>World Journal of Gastroenterology</i> , 2006, 12, 5978.	1.4	104
133	Topical Treatment of Distal Active Ulcerative Colitis With Beclomethasone Dipropionate or Mesalamine. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, 291-297.	1.1	59
134	Anti- <i>Saccharomyces cerevisiae</i> and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 881-887.	1.9	51
135	Probiotic Therapy in the Prevention of Pouchitis Onset: Decreased Interleukin-1 β , Interleukin-8, and Interferon- γ Gene Expression. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 447-454.	0.9	61
136	Local Injection of Infliximab for the Treatment of Perianal Crohn's Disease. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 768-774.	0.7	96
137	Probiotic Therapy to Prevent Pouchitis Onset. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 1493.	0.7	9
138	Variants of CARD15 are Associated with an Aggressive Clinical Course of Crohn's Disease-An IG-IBD Study. <i>American Journal of Gastroenterology</i> , 2005, 100, 84-92.	0.2	116
139	Management of Inflammatory Bowel Disease: Does Rifaximin Offer Any Promise?. <i>Chemotherapy</i> , 2005, 51, 96-102.	0.8	20
140	VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2005, 100, 1539-1546.	0.2	659
141	VSL#3: An Analysis of Basic and Clinical Contributions in Probiotic Therapeutics. <i>Gastroenterology Clinics of North America</i> , 2005, 34, 499-513.	1.0	30
142	Probiotics and barrier function in colitis. <i>Gut</i> , 2005, 54, 898-900.	6.1	21
143	Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. <i>Gut</i> , 2004, 53, 108-114.	6.1	783
144	Modulation of human dendritic cell phenotype and function by probiotic bacteria. <i>Gut</i> , 2004, 53, 1602-1609.	6.1	483

#	ARTICLE	IF	CITATIONS
145	CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue. <i>International Journal of Colorectal Disease</i> , 2004, 19, 165-170.	1.0	18
146	Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease study. <i>Digestive and Liver Disease</i> , 2004, 36, 121-124.	0.4	31
147	Management of pouch dysfunction or pouchitis with an ileoanal pouch. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 993-1006.	1.0	12
148	Diagnosis and treatment of pouchitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2003, 17, 75-87.	1.0	37
149	The effect of transient intestinal ischemia on inflammatory parameters. <i>International Journal of Colorectal Disease</i> , 2003, 18, 78-85.	1.0	24
150	Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. <i>FEMS Immunology and Medical Microbiology</i> , 2003, 38, 165-172.	2.7	241
151	Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1471-1480.	1.9	94
152	Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. <i>Clinical and Experimental Immunology</i> , 2003, 132, 473-476.	1.1	84
153	Probiotics for the treatment of postoperative complications following intestinal surgery. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2003, 17, 821-831.	1.0	41
154	VSL3 probiotic mixture induces remission in patients with active ulcerative colitis. <i>Gastroenterology</i> , 2003, 124, A377.	0.6	28
155	Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. <i>Gastroenterology</i> , 2003, 124, 1202-1209.	0.6	1,048
156	Standard Treatment of Ulcerative Colitis. <i>Digestive Diseases</i> , 2003, 21, 157-167.	0.8	37
157	Prophylaxis of pouchitis onset with probiotic therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 835.	0.8	10
158	Probiotics in gastroenterology. <i>Current Opinion in Gastroenterology</i> , 2002, 18, 235-239.	1.0	15
159	Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 909-917.	1.9	185
160	Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1109-1116.	1.9	119
161	Variable Response to Probiotics in Two Models of Experimental Colitis in Rats. <i>Inflammatory Bowel Diseases</i> , 2002, 8, 399-406.	0.9	115
162	Ileal pouchitis-related arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2002, 32, 204-205.	1.6	4

#	ARTICLE	IF	CITATIONS
163	Efficacy of a symbiotic preparation on functional intestinal disorders (FD) with altered bowel habit: A double-blind controlled study. <i>Gastroenterology</i> , 2001, 120, A750-A751.	0.6	1
164	Probiotics and antibiotics in inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2001, 17, 331-335.	1.0	25
165	Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 251-256.	1.9	79
166	Activation of signal-transducer and activator of transcription 1 (STAT1) in pouchitis. <i>Clinical and Experimental Immunology</i> , 2001, 123, 395-401.	1.1	26
167	Bacteria as the cause of ulcerative colitis. <i>Gut</i> , 2001, 48, 132-135.	6.1	169
168	Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. <i>American Journal of Gastroenterology</i> , 2001, 96, 2691-2699.	0.2	193
169	Role of probiotics in inflammatory bowel disease and intestinal infections. <i>Expert Opinion on Therapeutic Patents</i> , 2001, 11, 1277-1283.	2.4	1
170	Probiotics in infective diarrhoea and inflammatory bowel diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 489-493.	1.4	114
171	MCP-3 in inflammatory bowel disease Reply. <i>Gut</i> , 2000, 47, 155-155.	6.1	2
172	Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. <i>Gastroenterology</i> , 2000, 119, 305-309.	0.6	1,373
173	Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo controlled trial. <i>Gastroenterology</i> , 2000, 118, A190.	0.6	26
174	A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 381-388.	1.9	57
175	Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 713-718.	1.9	214
176	Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1103-1108.	1.9	485
177	Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus "A GISC study. <i>European Journal of Human Genetics</i> , 1999, 7, 567-573.	1.4	81
178	Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. <i>Digestive Diseases and Sciences</i> , 1999, 44, 1220-1221.	1.1	135
179	Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative?. <i>Gastroenterology</i> , 1999, 116, 1246-1249.	0.6	188
180	Relapsing ulcerative colitis after spinal cord stimulation: A case of intestinal neurogenic inflammation?. <i>Gastroenterology</i> , 1999, 117, 1256-1257.	0.6	9

#	ARTICLE	IF	CITATIONS
181	Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor- α in ulcerative colitis. <i>American Journal of Gastroenterology</i> , 1999, 94, 2923-2928.	0.2	74
182	Increased Expression of IP-10, IL-8, MCP-1, and MCP-3 in Ulcerative Colitis. <i>American Journal of Pathology</i> , 1999, 155, 331-336.	1.9	259
183	Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. <i>Diseases of the Colon and Rectum</i> , 1998, 41, 93-97.	0.7	127
184	Rifaximin systemic absorption in patients with ulcerative colitis. <i>European Journal of Clinical Pharmacology</i> , 1998, 54, 91-93.	0.8	38
185	Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 1998, 12, 361-366.	1.9	52
186	Recognition of Bactericidal/Permeability-Increasing Protein by Perinuclear Anti-Neutrophil Cytoplasmic Antibody-Positive Sera from Ulcerative Colitis Patients: Prevalence and Clinical Significance. <i>Scandinavian Journal of Gastroenterology</i> , 1998, 33, 1284-1288.	0.6	17
187	Intracolonic release of nitric oxide during trinitrobenzene sulfonic acid rat colitis. <i>Digestive Diseases and Sciences</i> , 1997, 42, 2606-2611.	1.1	19
188	Medical treatment of ulcerative colitis. <i>Current Opinion in Gastroenterology</i> , 1996, 12, 352-355.	1.0	3
189	Prediction of relapse in patients with Crohn's disease in remission. <i>European Journal of Gastroenterology and Hepatology</i> , 1994, 6, 955-962.	0.8	30
190	Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients. <i>Digestive Diseases and Sciences</i> , 1994, 39, 2589-2594.	1.1	61
191	Mucosal concentrations of interleukin-1 β , interleukin-6, interleukin-8, and tumor necrosis factor- α in pelvic ileal pouches. <i>Digestive Diseases and Sciences</i> , 1994, 39, 1525-1531.	1.1	69
192	Respiratory burst of circulating polymorphonuclear leukocytes and plasma elastase levels in patients with inflammatory bowel disease in remission. <i>Digestive Diseases and Sciences</i> , 1994, 39, 550-554.	1.1	13
193	p-ANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosis. <i>Lancet, The</i> , 1994, 344, 886-887.	6.3	64
194	Macrophage subpopulations and interleukin-1 β tissue levels in pelvic ileal pouches. <i>European Journal of Gastroenterology and Hepatology</i> , 1994, 6, 217-222.	0.8	3
195	Comparative trial of methylprednisolone and budesonide enemas in active distal ulcerative colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 1994, 6, 125-130.	0.8	55
196	Comparison of scintigraphy with indium-111 leukocyte scan and ultrasonography in assessment of x-ray-demonstrated lesions of crohn's disease. <i>Digestive Diseases and Sciences</i> , 1993, 38, 433-437.	1.1	37
197	Polyunsaturated fatty acid pattern and fish oil treatment in inflammatory bowel disease.. <i>Gut</i> , 1993, 34, 1289-1290.	6.1	7
198	Clinical management of inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 1993, 9, 571-581.	1.0	1

#	ARTICLE	IF	CITATIONS
199	Changes in Splanchnic Hemodynamics in Inflammatory Bowel Disease Non-Invasive Assessment by Doppler Ultrasound Flowmetry. <i>Scandinavian Journal of Gastroenterology</i> , 1992, 27, 501-507.	0.6	90
200	Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. <i>Digestive Diseases and Sciences</i> , 1992, 37, 1890-1897.	1.1	88
201	Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. <i>Digestive Diseases and Sciences</i> , 1992, 37, 29-32.	1.1	70
202	Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. <i>Digestive Diseases and Sciences</i> , 1991, 36, 174-178.	1.1	65
203	Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis.. <i>Gut</i> , 1991, 32, 929-931.	6.1	105
204	Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. <i>International Journal of Colorectal Disease</i> , 1990, 5, 79-81.	1.0	52
205	5-Aminosalicylic acid suppositories in the management of ulcerative colitis. <i>Diseases of the Colon and Rectum</i> , 1989, 32, 398-399.	0.7	15
206	Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis. <i>Diseases of the Colon and Rectum</i> , 1986, 29, 108-110.	0.7	45